Profund Advisors’s Dyne Therapeutics DYN Stock Holding History

Profund Advisors’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.49M	Sell	82,138 -4,608	-5%	-$79.5K	0.05%	250
2025 Q4	$1.7M	Buy	86,746 +40,766	+89%	+$772K	0.05%	249
2025 Q3	$582K	Buy	45,980 +22,338	+94%	+$255K	0.02%	465
2025 Q2	$225K	Sell	23,642 -7,077	-23%	-$77.9K	0.01%	834
2025 Q1	$321K	Sell	30,719 -1,875	-6%	-$26.8K	0.01%	641
2024 Q4	$768K	Sell	32,594 -298	-0.9%	-$8.81K	0.03%	353
2024 Q3	$1.18M	Buy	32,892 +5,471	+20%	+$218K	0.04%	287
2024 Q2	$968K	Sell	27,421 -26,026	-49%	-$756K	0.04%	306
2024 Q1	$1.52M	Buy	53,447 +26,485	+98%	+$599K	0.06%	225
2023 Q4	$359K	Buy	26,962 +3,169	+13%	+$31K	0.02%	687
2023 Q3	$213K	Buy	23,793 +2,131	+10%	+$23K	0.01%	850
2023 Q2	$244K	Buy	+21,662	New	+$256K	0.01%	848

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Profund Advisors's DYN Position: Q1 2026 in Review

Profund Advisors reduced its Dyne Therapeutics (DYN) stake by 5.3% in Q1 2026, selling an estimated $79.5K and leaving 82,138 shares worth $1.49M. The position accounts for 0.05% of the portfolio, ranked #250.

Profund Advisors first reported a position in DYN in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.7M in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Profund Advisors held 82,138 shares of Dyne Therapeutics worth $1.49M as of Q1 2026.
Profund Advisors sold 4,608 Dyne Therapeutics shares in Q1 2026, an estimated $79.5K.
Dyne Therapeutics made up 0.05% of Profund Advisors's portfolio in Q1 2026, its #250 holding.
Profund Advisors first reported a position in Dyne Therapeutics in Q2 2023 and has held it in 12 quarters since.
Profund Advisors's Dyne Therapeutics position peaked at $1.7M in Q4 2025.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.